T-Cell Repertoire in Tumor Radiation: The Emerging Frontier as a Radiotherapy Biomarker.
TCR repertoire
abscopal effect
biomarkers
cancer
immunotherapy
radiotherapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 May 2022
27 May 2022
Historique:
received:
06
05
2022
revised:
20
05
2022
accepted:
26
05
2022
entrez:
10
6
2022
pubmed:
11
6
2022
medline:
11
6
2022
Statut:
epublish
Résumé
Radiotherapy (RT) is a therapeutic modality that aims to eliminate malignant cells through the induction of DNA damage in the irradiated tumor site. In addition to its cytotoxic properties, RT also induces mechanisms that result in the promotion of antitumor immunity both locally within the irradiation field but also at distant tumor lesions, a phenomenon that is known as the "abscopal" effect. Because the immune system is capable of sensing the effects of RT, several treatment protocols have been assessing the synergistic role of radiotherapy combined with immunotherapy, collectively referred to as radioimmunotherapy. Herein, we discuss mechanistic insights underlying RT-based immunomodulation, which also enhance our understanding of how RT regulates antitumor T-cell-mediated immunity. Such knowledge is essential for the discovery of predictive biomarkers and for the improvement of clinical trials investigating the efficacy of radio-immunotherapeutic modalities in cancer patients.
Identifiants
pubmed: 35681654
pii: cancers14112674
doi: 10.3390/cancers14112674
pmc: PMC9179913
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : European Regional Development Fund and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call Research-Create-Innovate
ID : Project code: Τ2EDK-03266, project acronym and title: "BIOKAKETRA-Identification of genomic and transcriptomic prognostic bio-signatures in head and neck cancer"; Project code: T2EDK-02218, project acronym and title: "B-PREIMMUN, Immune and Molecular circ
Références
Nat Med. 2007 Jan;13(1):54-61
pubmed: 17187072
Adv Pharmacol. 2011;61:301-32
pubmed: 21586363
Cancer Lett. 2015 Nov 28;368(2):230-7
pubmed: 25888451
J Clin Invest. 2010 Mar;120(3):694-705
pubmed: 20179352
Nature. 2008 Oct 2;455(7213):674-8
pubmed: 18724357
J Exp Med. 2006 May 15;203(5):1259-71
pubmed: 16636135
Mol Oncol. 2021 Nov;15(11):2958-2968
pubmed: 34402187
Immunol Rev. 2019 Jul;290(1):24-38
pubmed: 31355488
Immunity. 2006 Jan;24(1):93-103
pubmed: 16413926
Cancer Res. 2015 Jun 1;75(11):2232-42
pubmed: 25858148
Proc Natl Acad Sci U S A. 2020 Sep 22;117(38):23721-23729
pubmed: 32900949
J Immunol. 2008 Mar 1;180(5):3132-9
pubmed: 18292536
Curr Opin Pharmacol. 2016 Aug;29:7-16
pubmed: 27209048
Front Oncol. 2012 Oct 26;2:153
pubmed: 23112958
Nat Immunol. 2015 Jun;16(6):609-17
pubmed: 25915731
Front Immunol. 2017 Mar 13;8:229
pubmed: 28348554
Cancer Res. 2011 Dec 15;71(24):7433-41
pubmed: 22006996
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
Nat Rev Cancer. 2018 May;18(5):313-322
pubmed: 29449659
Oncol Lett. 2021 Jun;21(6):446
pubmed: 33868484
Cell. 2014 Dec 18;159(7):1549-62
pubmed: 25525874
Biomed Pharmacother. 2021 Jul;139:111607
pubmed: 33965730
Transl Oncol. 2022 May;19:101366
pubmed: 35219093
Cancer Immunol Immunother. 2014 Mar;63(3):259-71
pubmed: 24357146
Sci Immunol. 2016 Sep;1(3):
pubmed: 28018989
Front Immunol. 2016 Dec 22;7:610
pubmed: 28066420
Proc Natl Acad Sci U S A. 1989 Dec;86(24):10104-7
pubmed: 2602359
J Clin Invest. 2009 May;119(5):1136-49
pubmed: 19381014
Nat Med. 2018 Dec;24(12):1845-1851
pubmed: 30397353
Am J Pathol. 2005 Sep;167(3):627-35
pubmed: 16127144
Front Immunol. 2015 Oct 08;6:505
pubmed: 26500646
J Exp Med. 2014 May 5;211(5):781-90
pubmed: 24778419
Nature. 2017 Apr 13;544(7649):250-254
pubmed: 28371798
Front Immunol. 2014 Jul 04;5:299
pubmed: 25071762
Prostate. 2008 Sep 1;68(12):1319-29
pubmed: 18561247
Cancer Res. 2011 Apr 1;71(7):2488-96
pubmed: 21300764
Int J Mol Sci. 2020 Oct 31;21(21):
pubmed: 33142765
J Clin Invest. 2014 Feb;124(2):687-95
pubmed: 24382348
Radiat Res. 2020 Dec 1;194(6):688-697
pubmed: 33348372
Nat Commun. 2017 Jun 09;8:15618
pubmed: 28598415
Radiat Res. 2010 Apr;173(4):406-17
pubmed: 20334512
Cancer Res. 2014 Dec 15;74(24):7250-9
pubmed: 25377469
Structure. 2012 Dec 5;20(12):2161-73
pubmed: 23142347
Cancer Chemother Pharmacol. 2013 Apr;71(4):1041-50
pubmed: 23385782
Target Oncol. 2015 Mar;10(1):111-23
pubmed: 24928772
Transl Oncol. 2012 Dec;5(6):404-7
pubmed: 23323154
Immunity. 2014 Nov 20;41(5):830-42
pubmed: 25517615
Cancer Cell. 2013 Nov 11;24(5):589-602
pubmed: 24209604
Cell Commun Signal. 2022 Apr 7;20(1):44
pubmed: 35392976
J Biol Chem. 2010 Mar 5;285(10):7176-86
pubmed: 19858205
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
Cancer Res. 2010 Apr 1;70(7):2697-706
pubmed: 20215523
J Biol Chem. 2008 Aug 22;283(34):23419-28
pubmed: 18544535
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):862-70
pubmed: 14967443
Science. 2013 Feb 15;339(6121):786-91
pubmed: 23258413
Commun Biol. 2020 Nov 27;3(1):720
pubmed: 33247183
Br J Pharmacol. 2008 Mar;153 Suppl 1:S457-64
pubmed: 18311159
J Hematol Oncol. 2021 Jun 12;14(1):92
pubmed: 34118979
Int J Mol Sci. 2021 Jul 04;22(13):
pubmed: 34281259
Strahlenther Onkol. 2018 Jun;194(6):509-519
pubmed: 29500551
Am J Physiol Cell Physiol. 2015 Nov 1;309(9):C569-79
pubmed: 26310815
Nature. 2017 May 4;545(7652):60-65
pubmed: 28397821
J Immunother Cancer. 2021 Apr;9(4):
pubmed: 33827904
Biochem Biophys Res Commun. 2018 Sep 3;503(1):138-145
pubmed: 29870684
Cancer Res. 2004 Jun 15;64(12):4328-37
pubmed: 15205348
Mol Cell. 2013 Apr 11;50(1):5-15
pubmed: 23478444
Cancer Res. 2014 Oct 1;74(19):5458-68
pubmed: 25274032
Int J Oncol. 2022 Jun;60(6):
pubmed: 35445738
Nat Rev Cancer. 2015 Jul;15(7):409-25
pubmed: 26105538
Cancer Res. 2002 Mar 1;62(5):1462-70
pubmed: 11888921
Cell. 2012 Jul 6;150(1):165-78
pubmed: 22770218
Nat Rev Immunol. 2008 Jul;8(7):533-44
pubmed: 18551128
Int J Cancer. 2016 Jul 15;139(2):396-403
pubmed: 26945902
Blood. 2010 Feb 18;115(7):1461-71
pubmed: 20008303
Front Immunol. 2012 Jul 05;3:190
pubmed: 22783261
Int J Mol Sci. 2021 Oct 14;22(20):
pubmed: 34681719
Cancer Res. 2013 May 1;73(9):2782-94
pubmed: 23418320
Int J Radiat Oncol Biol Phys. 2021 May 1;110(1):21-34
pubmed: 30836165
J Immunol. 2005 Jun 15;174(12):7516-23
pubmed: 15944250
Int J Med Sci. 2012;9(3):193-9
pubmed: 22408567